BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30364958)

  • 1. Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
    Vaz P; Buck WC; Bhatt N; Bila D; Auld A; Houston J; Cossa L; Alfredo C; Jobarteh K; Sabatier J; Macassa E; Sousa A; DeVos J; Jani I; Yang C
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):6-13. PubMed ID: 30364958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
    Rewari BB; Bachani D; Rajasekaran S; Deshpande A; Chan PL; Srikantiah P
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):610-4. PubMed ID: 20890211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
    Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
    Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
    Gupta RK; Ford D; Mulenga V; Walker AS; Kabamba D; Kalumbi M; Grant PR; Ferrier A; Pillay D; Gibb DM; Chintu C
    Pediatr Infect Dis J; 2010 Aug; 29(8):e57-62. PubMed ID: 20508547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
    Sophan S; Meng CY; Pean P; Harwell J; Hutton E; Trzmielina S; Somasundaran M; Luzuriaga K; Pugatch D
    Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):126-37. PubMed ID: 20578491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
    Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
    PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
    Luo XL; Mo LD; Su GS; Huang JP; Wu JY; Su HZ; Huang WH; Luo SD; Ni ZY
    J Pharmacol Sci; 2019 Apr; 139(4):275-279. PubMed ID: 30928089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage.
    Shalit P; Farrell P; McClarty M
    HIV Clin Trials; 2004; 5(1):62-4. PubMed ID: 15002088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.